Jason Mellad

Dr Jason Mellad is Co-founder and CEO of OtoImmune, a precision immunology company focused on revolutionising the early detection, management and treatment of autoimmune and other immune-mediated inflammatory diseases. Previously he was CEO of life science venture builder fund Start Codon and epigenomic biomarker discovery pioneer Cambridge Epigenetix (now Biomodal). Jason holds a PhD in Medicine from the University of Cambridge